Titre :

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT.

Auteur(s) :

Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Chevret, Sylvie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Finke, J. [Auteur]
Ehninger, G. [Auteur]
Ayuk, F. [Auteur]
Beelen, D. [Auteur]
Koster, L. [Auteur]
Ganser, A. [Auteur]
Volin, L. [Auteur]
Sengeloev, H. [Auteur]
Michallet, Mauricette [Auteur]
Tischer, J. [Auteur]
Jindra, P. [Auteur]
Cascon, M. J. P. [Auteur]
Koc, Y. [Auteur]
Arat, M. [Auteur]
Tomaszewska, A. [Auteur]
Hayden, P. [Auteur]
De Witte, T. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Kröger, N. [Auteur]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Numéro :

57

Pagination :

768–774

Date de publication :

2022-03-02

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with ...
Lire la suite >While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T02:11:41Z
2024-03-29T08:18:29Z